Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 6/20 | 0.70 |
| ▸ | ESR1 | P03372 | 5/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.60 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.51 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5359582 | 0.95 | ESR1 (0.65) | ESR2ESR1HDAC6HDAC8ABHD6 | |
| SCHEMBL10214641 | 0.89 | HDAC6 (0.56) | ESR2ESR1HDAC6HDAC8ABHD6 | |
| SCHEMBL12485928 | 0.87 | ESR1 (0.55) | ESR2ESR1HDAC6HDAC8NAMPT | |
| SCHEMBL12682930 | 0.85 | HDAC6 (0.56) | ESR2ESR1HDAC6HDAC8ACACB | |
| SCHEMBL1027755 | 0.85 | HDAC6 (0.56) | ESR2ESR1HDAC6HDAC8ACACB | |
| SCHEMBL31276014 | 0.85 | HDAC6 (0.56) | ESR2ESR1HDAC6HDAC8ACACB | |
| SCHEMBL3895230 | 0.83 | ESR1 (1.00) | ESR2ESR1HDAC6HDAC8ABHD6 | |
| SCHEMBL3024823 | 0.82 | ESR2 (0.69) | ESR2ESR1HDAC6HDAC8ABHD6 | |
| SCHEMBL30301758 | 0.82 | ESR2 (0.69) | ESR2ESR1HDAC6HDAC8ABHD6 | |
| SCHEMBL1263724 | 0.82 | HDAC6 (0.53) | ESR2ESR1HDAC6HDAC8ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713313-A2 | TETRAHYDRONAPTHYRIDINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | Springworks Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20240417398-A1 | TETRAHYDRONAPTHYRIDINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. | 2024-12-19 | — | — | US | disclosed |
| WO-2024238763-A2 | TETRAHYDRONAPTHYRIDINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-4219504-A1 | MACROCYCLIC TLR7 AGONIST, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Visonpharma Co., Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
| US-7268142-B2 | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline | PFIZER INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268142-B2 | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline | PFIZER INC. (US) | 2007-09-11 | — | — | US | disclosed |
| WO-2005082883-A2 | TETRAHYDROISOQUINOLINYL DERIVATIVES OF QUINAZOLINE AND ISOQUINOLINE | PFIZER PRODUCTS INC. (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417398-A1 | TETRAHYDRONAPTHYRIDINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | YAP1, TEAD2, TEAD1 | ESR2 477/4885ESR1 2104/4885HDAC6 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.